Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Blocking nuclear export of HSPA8 after heat shock stress severely alters cell survival.

Wang F, Bonam SR, Schall N, Kuhn L, Hammann P, Chaloin O, Madinier JB, Briand JP, Page N, Muller S.

Sci Rep. 2018 Nov 14;8(1):16820. doi: 10.1038/s41598-018-34887-6.

2.

Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.

Dieker J, Berden JH, Bakker M, Briand JP, Muller S, Voll R, Sjöwall C, Herrmann M, Hilbrands LB, van der Vlag J.

PLoS One. 2016 Oct 25;11(10):e0165373. doi: 10.1371/journal.pone.0165373. eCollection 2016.

3.

Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide.

Macri C, Wang F, Tasset I, Schall N, Page N, Briand JP, Cuervo AM, Muller S.

Autophagy. 2015;11(3):472-86. doi: 10.1080/15548627.2015.1017179.

4.

Deimination of linker histones links neutrophil extracellular trap release with autoantibodies in systemic autoimmunity.

Dwivedi N, Neeli I, Schall N, Wan H, Desiderio DM, Csernok E, Thompson PR, Dali H, Briand JP, Muller S, Radic M.

FASEB J. 2014 Jul;28(7):2840-51. doi: 10.1096/fj.13-247254. Epub 2014 Mar 26.

5.

Generation of self-peptides to treat systemic lupus erythematosus.

Briand JP, Schall N, Muller S.

Methods Mol Biol. 2014;1134:173-92. doi: 10.1007/978-1-4939-0326-9_13.

PMID:
24497362
6.

The pseudopeptide HB-19 binds to cell surface nucleolin and inhibits angiogenesis.

Birmpas C, Briand JP, Courty J, Katsoris P.

Vasc Cell. 2012 Dec 24;4(1):21. doi: 10.1186/2045-824X-4-21.

7.

Nucleolin mediates the antiangiogenesis effect of the pseudopeptide N6L.

Birmpas C, Briand JP, Courty J, Katsoris P.

BMC Cell Biol. 2012 Nov 13;13:32. doi: 10.1186/1471-2121-13-32.

8.

Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release.

Destouches D, Huet E, Sader M, Frechault S, Carpentier G, Ayoul F, Briand JP, Menashi S, Courty J.

J Biol Chem. 2012 Dec 21;287(52):43685-93. doi: 10.1074/jbc.M112.380402. Epub 2012 Oct 29.

9.

Peptide-based approaches to treat lupus and other autoimmune diseases.

Schall N, Page N, Macri C, Chaloin O, Briand JP, Muller S.

J Autoimmun. 2012 Sep;39(3):143-53. doi: 10.1016/j.jaut.2012.05.016. Epub 2012 Jun 22. Review.

PMID:
22727561
10.

Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome.

Janko C, André S, Munoz LE, Briand JP, Schorn C, Winkler S, Schiller M, Andreoli L, Manfredi AA, Isenberg DA, Schett G, Gabius HJ, Muller S, Herrmann M.

Lupus. 2012 Jun;21(7):781-3. doi: 10.1177/0961203312443422.

PMID:
22635232
11.

HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase.

Lecoeur H, Borgne-Sanchez A, Chaloin O, El-Khoury R, Brabant M, Langonné A, Porceddu M, Brière JJ, Buron N, Rebouillat D, Péchoux C, Deniaud A, Brenner C, Briand JP, Muller S, Rustin P, Jacotot E.

Cell Death Dis. 2012 Mar 15;3:e282. doi: 10.1038/cddis.2012.21.

12.

Single insulin-specific CD8+ T cells show characteristic gene expression profiles in human type 1 diabetes.

Luce S, Lemonnier F, Briand JP, Coste J, Lahlou N, Muller S, Larger E, Rocha B, Mallone R, Boitard C.

Diabetes. 2011 Dec;60(12):3289-99. doi: 10.2337/db11-0270. Epub 2011 Oct 13.

13.

Structure-based design of short peptide ligands binding onto the E. coli processivity ring.

Wolff P, Oliéric V, Briand JP, Chaloin O, Dejaegere A, Dumas P, Ennifar E, Guichard G, Wagner J, Burnouf DY.

J Med Chem. 2011 Jul 14;54(13):4627-37. doi: 10.1021/jm200311m. Epub 2011 Jun 9.

PMID:
21619076
14.

A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins.

Destouches D, Page N, Hamma-Kourbali Y, Machi V, Chaloin O, Frechault S, Birmpas C, Katsoris P, Beyrath J, Albanese P, Maurer M, Carpentier G, Strub JM, Van Dorsselaer A, Muller S, Bagnard D, Briand JP, Courty J.

Cancer Res. 2011 May 1;71(9):3296-305. doi: 10.1158/0008-5472.CAN-10-3459. Epub 2011 Mar 17.

15.

A therapeutic peptide in lupus alters autophagic processes and stability of MHCII molecules in MRL/lpr B cells.

Page N, Gros F, Schall N, Briand JP, Muller S.

Autophagy. 2011 May;7(5):539-40. Epub 2011 May 1.

PMID:
21282971
16.

HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus.

Page N, Gros F, Schall N, Décossas M, Bagnard D, Briand JP, Muller S.

Ann Rheum Dis. 2011 May;70(5):837-43. doi: 10.1136/ard.2010.139832. Epub 2010 Dec 20.

17.

Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

El Khoury D, Destouches D, Lengagne R, Krust B, Hamma-Kourbali Y, Garcette M, Niro S, Kato M, Briand JP, Courty J, Hovanessian AG, Prévost-Blondel A.

BMC Cancer. 2010 Jun 24;10:325. doi: 10.1186/1471-2407-10-325.

18.

Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice.

Lacotte S, Dumortier H, Décossas M, Briand JP, Muller S.

J Immunol. 2010 Apr 1;184(7):3937-45. doi: 10.4049/jimmunol.0902595. Epub 2010 Feb 24.

19.

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H.

Cancer Res. 2010 Feb 1;70(3):1101-10. doi: 10.1158/0008-5472.CAN-09-2889. Epub 2010 Jan 26.

20.

Emerging peptide therapeutics for inflammatory autoimmune diseases.

Briand JP, Muller S.

Curr Pharm Des. 2010;16(9):1136-42. Review.

PMID:
20030611
21.

Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone.

Claudon P, Violette A, Lamour K, Decossas M, Fournel S, Heurtault B, Godet J, Mély Y, Jamart-Grégoire B, Averlant-Petit MC, Briand JP, Duportail G, Monteil H, Guichard G.

Angew Chem Int Ed Engl. 2010;49(2):333-6. doi: 10.1002/anie.200905591. No abstract available.

PMID:
19957258
22.

Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies.

van Bavel CC, Dieker J, Muller S, Briand JP, Monestier M, Berden JH, van der Vlag J.

Mol Immunol. 2009 Dec;47(2-3):511-6. doi: 10.1016/j.molimm.2009.08.009. Epub 2009 Sep 10.

PMID:
19747733
23.

A flavivirus protein M-derived peptide directly permeabilizes mitochondrial membranes, triggers cell death and reduces human tumor growth in nude mice.

Brabant M, Baux L, Casimir R, Briand JP, Chaloin O, Porceddu M, Buron N, Chauvier D, Lassalle M, Lecoeur H, Langonné A, Dupont S, Déas O, Brenner C, Rebouillat D, Muller S, Borgne-Sanchez A, Jacotot E.

Apoptosis. 2009 Oct;14(10):1190-203. doi: 10.1007/s10495-009-0394-y.

PMID:
19693674
24.

Mixing urea and amide bonds: synthesis and self-organization of new hybrid oligomers.

Fischer L, Lena G, Briand JP, Didierjean C, Guichard G.

Adv Exp Med Biol. 2009;611:39-40. No abstract available.

PMID:
19400084
25.

The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells.

Page N, Schall N, Strub JM, Quinternet M, Chaloin O, Décossas M, Cung MT, Van Dorsselaer A, Briand JP, Muller S.

PLoS One. 2009;4(4):e5273. doi: 10.1371/journal.pone.0005273. Epub 2009 Apr 23.

26.

Immunomodulatory consequences of ODN CpG-polycation complexes.

Partidos CD, Hoebeke J, Wieckowski S, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S.

Methods. 2009 Dec;49(4):328-33. doi: 10.1016/j.ymeth.2009.03.005. Epub 2009 Mar 18. Review.

PMID:
19303048
27.

Control of duplex formation and columnar self-assembly with heterogeneous amide/urea macrocycles.

Fischer L, Decossas M, Briand JP, Didierjean C, Guichard G.

Angew Chem Int Ed Engl. 2009;48(9):1625-8. doi: 10.1002/anie.200804019.

PMID:
19170154
28.

The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells.

Losfeld ME, Khoury DE, Mariot P, Carpentier M, Krust B, Briand JP, Mazurier J, Hovanessian AG, Legrand D.

Exp Cell Res. 2009 Jan 15;315(2):357-69. doi: 10.1016/j.yexcr.2008.10.039. Epub 2008 Nov 6.

PMID:
19026635
29.

Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes.

Toma A, Laïka T, Haddouk S, Luce S, Briand JP, Camoin L, Connan F, Lambert M, Caillat-Zucman S, Carel JC, Muller S, Choppin J, Lemonnier F, Boitard C.

Diabetes. 2009 Feb;58(2):394-402. doi: 10.2337/db08-0599. Epub 2008 Nov 14.

30.

Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.

Castelli FA, Houitte D, Munier G, Szely N, Lecoq A, Briand JP, Muller S, Maillere B.

Eur J Immunol. 2008 Oct;38(10):2821-31. doi: 10.1002/eji.200738072.

31.

A novel receptor - ligand pathway for entry of Francisella tularensis in monocyte-like THP-1 cells: interaction between surface nucleolin and bacterial elongation factor Tu.

Barel M, Hovanessian AG, Meibom K, Briand JP, Dupuis M, Charbit A.

BMC Microbiol. 2008 Sep 12;8:145. doi: 10.1186/1471-2180-8-145.

32.

Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type.

Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A.

Nat Nanotechnol. 2007 Feb;2(2):108-13. doi: 10.1038/nnano.2006.209. Epub 2007 Jan 28. No abstract available.

PMID:
18654229
33.

Propensity for local folding induced by the urea fragment in short-chain oligomers.

Fischer L, Didierjean C, Jolibois F, Semetey V, Manuel Lozano J, Briand JP, Marraud M, Poteau R, Guichard G.

Org Biomol Chem. 2008 Jul 21;6(14):2596-610. doi: 10.1039/b801139g. Epub 2008 May 15.

PMID:
18600281
34.

Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.

Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG.

PLoS One. 2008 Jun 18;3(6):e2518. doi: 10.1371/journal.pone.0002518.

35.

Exploring helical folding of oligoureas during chain elongation by high-resolution magic-angle-spinning (HRMAS) NMR spectroscopy.

Violette A, Lancelot N, Poschalko A, Piotto M, Briand JP, Raya J, Elbayed K, Bianco A, Guichard G.

Chemistry. 2008;14(13):3874-82. doi: 10.1002/chem.200701923.

PMID:
18381712
36.

The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1.

Benferhat R, Sanchez-Martinez S, Nieva JL, Briand JP, Hovanessian AG.

Mol Immunol. 2008 Apr;45(7):1963-75. Epub 2007 Dec 3.

PMID:
18054388
37.
38.

Insights into spatial configuration of a galactosylated epitope required to trigger arthritogenic T-cell receptors specific for the sugar moiety.

Glatigny S, Blaton MA, Marin J, Mistou S, Briand JP, Guichard G, Fournier C, Chiocchia G.

Arthritis Res Ther. 2007;9(5):R92.

39.

Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus.

Dieker JW, Fransen JH, van Bavel CC, Briand JP, Jacobs CW, Muller S, Berden JH, van der Vlag J.

Arthritis Rheum. 2007 Jun;56(6):1921-33.

40.

Heteroclitic properties of mixed alpha- and aza-beta3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome.

Dali H, Busnel O, Hoebeke J, Bi L, Decker P, Briand JP, Baudy-Floc'h M, Muller S.

Mol Immunol. 2007 Apr;44(11):3024-36. Epub 2007 Feb 9.

PMID:
17292472
41.

Peptido-targeting of the mitochondrial transition pore complex for therapeutic apoptosis induction.

Deniaud A, Hoebeke J, Briand JP, Muller S, Jacotot E, Brenner C.

Curr Pharm Des. 2006;12(34):4501-11. Review.

PMID:
17168756
42.

Porous 3-D honeycomb architecture by self-assembly of helical H-bonded molecular tapes.

Schaffner AP, Lena G, Roussel S, Wawrezinieck A, Aubry A, Briand JP, Didierjean C, Guichard G.

Chem Commun (Camb). 2006 Oct 21;(39):4069-71. Epub 2006 Sep 11. Erratum in: Chem Commun (Camb). 2006 Oct 21;(39):4146.

PMID:
17024251
43.

Therapeutic peptides: Targeting the mitochondrion to modulate apoptosis.

Jacotot E, Deniaud A, Borgne-Sanchez A, Touat Z, Briand JP, Le Bras M, Brenner C.

Biochim Biophys Acta. 2006 Sep-Oct;1757(9-10):1312-23. Epub 2006 Jul 14. Review.

44.

1,3,5-Triazepane-2,6-diones as structurally diverse and conformationally constrained dipeptide mimetics: identification of malaria liver stage inhibitors from a small pilot library.

Lena G, Lallemand E, Gruner AC, Boeglin J, Roussel S, Schaffner AP, Aubry A, Franetich JF, Mazier D, Landau I, Briand JP, Didierjean C, Rénia L, Guichard G.

Chemistry. 2006 Nov 15;12(33):8498-512.

PMID:
16927352
45.

Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells.

Borgne-Sanchez A, Dupont S, Langonné A, Baux L, Lecoeur H, Chauvier D, Lassalle M, Déas O, Brière JJ, Brabant M, Roux P, Péchoux C, Briand JP, Hoebeke J, Deniaud A, Brenner C, Rustin P, Edelman L, Rebouillat D, Jacotot E.

Cell Death Differ. 2007 Mar;14(3):422-35. Epub 2006 Aug 4.

46.

Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells.

Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, Briand JP, Prato M, Muller S, Bianco A.

Nano Lett. 2006 Jul;6(7):1522-8. Erratum in: Nano Lett. 2006 Dec;6(12):3003.

PMID:
16834443
47.

Design and activity of cationic fullerene derivatives as inhibitors of acetylcholinesterase.

Pastorin G, Marchesan S, Hoebeke J, Da Ros T, Ehret-Sabatier L, Briand JP, Prato M, Bianco A.

Org Biomol Chem. 2006 Jul 7;4(13):2556-62. Epub 2006 May 25.

PMID:
16791318
48.

HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.

Rey-Cuillé MA, Svab J, Benferhat R, Krust B, Briand JP, Muller S, Hovanessian AG.

J Pharm Pharmacol. 2006 Jun;58(6):759-67.

PMID:
16734977
49.

Mimicking helical antibacterial peptides with nonpeptidic folding oligomers.

Violette A, Fournel S, Lamour K, Chaloin O, Frisch B, Briand JP, Monteil H, Guichard G.

Chem Biol. 2006 May;13(5):531-8.

50.

Double functionalization of carbon nanotubes for multimodal drug delivery.

Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, Bianco A.

Chem Commun (Camb). 2006 Mar 21;(11):1182-4. Epub 2006 Feb 13.

PMID:
16518484

Supplemental Content

Loading ...
Support Center